Perjeta (pertuzumab) is a HER2/neu receptor antagonist used to treat HER2-positive breast cancer. It works by blocking HER2 receptors on cancer cells, inhibiting signals that drive tumor growth. It is given via an intravenous infusion by a healthcare provider.